查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571593

痤疮药物市场规模、份额、趋势分析报告：按类型、药物类别、给药方法、分销管道、地区、细分市场预测，2024-2030

Acne Drugs Market Size, Share & Trends Analysis Report By Type (Inflammatory, Non-inflammatory), By Therapeutic Class, By Mode Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

痤疮药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球痤疮药物市场规模将达到131.3亿美元，2024年至2030年复合年增长率为5.2%。

预计有几个因素将推动市场发展，包括生技药品的出现、不健康的生活方式和疾病盛行率的上升。

寻常性痤疮是最常见的皮肤病之一，影响全球 9.4% 的人。寻常性痤疮可以发生在任何年龄，但最常见于青少年。研究发现，超过85.0%的12岁至25岁族群有此症状。痤疮可以以多种不同的形式出现，从粉刺到囊性病变，这取决于其严重程度。

类视色素A和抗生素是痤疮治疗的主要药物。 2017 年，类视色素在治疗层级处于领先地位，预计这一趋势将持续到 2025 年。由于联合治疗的疗效更高、给药更容易且副作用更少，治疗领域正在转向联合治疗。

从给药方式来看，目前外用药物在市场上占据主导地位。严重时采用全身性药物如口服抗生素、荷尔蒙等药物。然而，生物製药（Gevokizumab 和 RA-18C3）的出现可能会加速注射给药途径的发展。生物製药针对具有缓解疾病潜力的发炎机制，使其比传统的局部治疗具有临床优势。

由于临床试验失败而停止或终止主要候选药物是市场面临的主要阻碍因素。首次推出时，Olumacostat glasaretil（Dermira；一种局部脂质合成抑制剂）预计将成为第一个具有异维A酸样作用且无明显副作用的局部抗痤疮药物。然而，该药物未能达到临床终点，并于 2018 年 3 月停产。同样，2018 年 7 月，SNA-001（银奈米粒子溶液）在与 810nm 和 1064nm 雷射结合测试时，在两项关键测试中失败。由于药物不可用，Thesan 从 II 期试验中撤回了 TSN2898。 Xenon 在 II 期临床试验失败后停止了 XEN801 的开发。

儘管痤疮是世界上最常见的皮肤病之一，但过去十年中痤疮治疗的创新相当有限。製药公司目前正在探索新的治疗方法，例如硬脂酰辅酶A去饱和酶抑制、黑皮质素受体拮抗剂和抗IL-1单株抗体。后期在研发线产品上市在即，预示着全球痤疮药物市场前景广阔。

痤疮药物市场报告亮点

  • 发炎痤疮占据市场主导地位，2023年占65.4%的份额。此部分的成长要素是导致发炎痤疮的细菌性皮肤感染疾病。
  • 非处方药 (OTC) 占据市场主导地位，2023 年占 35.9% 的份额。
  • 外用药物领域占据市场主导地位，2023 年占 47.5% 的份额。此细分市场的成长是由于外用产品的需求不断增加，因为它们易于使用、剂量准确且可作为非处方药使用。
  • 零售药局占据市场主导地位，2023年占37.5%的份额。
  • 2023年北美痤疮药物市场占据主导地位。痤疮药物市场的成长归因于痤疮盛行率的上升、医疗保健基础设施的发展以及涉及痤疮药物市场的公司的强大影响力。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章痤疮药物市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 痤疮药物市场分析工具
    • 波特的分析
    • PESTEL分析

第四章 痤疮药物市场：类型估计与趋势分析

  • 细分仪表板
  • 痤疮药物市场：类型变化分析，2023 年和 2030 年
  • 发炎性痤疮
  • 非发炎性痤疮

第五章痤疮药物市场：治疗层级的估计和趋势分析

  • 细分仪表板
  • 痤疮药物市场：2023 年和 2030 年治疗层级变异分析
  • 局部类视色素
  • 口服抗生素
  • 口服类视色素
  • 非处方药 (OTC)

第六章 痤疮药物市场：给药方式预估及趋势分析

  • 细分仪表板
  • 痤疮药物市场：2023年和2030年给药方法的变化分析
  • 外用
  • 口服
  • 注射

第七章 痤疮药物市场：分销通路估算及趋势分析

  • 细分仪表板
  • 痤疮药物市场：2023 年和 2030 年分销管道变化分析
  • 医院药房
  • 零售药房
  • 网路药房
  • 其他的

第八章痤疮药物市场：区域估计及趋势分析

  • 痤疮药物市场占有率（按地区），2023 年和 2030 年，
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • GALDERMA
    • Johnson &Johnson Services, Inc.
    • GSK plc.
    • Pfizer Inc.
    • AbbVie Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Bausch Health Companies Inc.
    • Nestle Skin Health SA
    • Bayer AG
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd
    • LEO Pharma A/S
    • Perrigo Company plc
简介目录
Product Code: GVR-2-68038-440-6

Acne Drugs Market Growth & Trends:

The global acne drugs market size is expected to reach USD 13.13 billion by 2030, according to a new report by Grand View Research, Inc., registering a 5.2% CAGR from 2024 to 2030. Several factors such as emergence of biologics, unhealthy lifestyle, and rising disease incidence are anticipated to drive the market.

Acne vulgaris is one of the most common dermatological disorders, affecting 9.4% people worldwide. Although the condition can affect people of all ages, it is most prevalent among teenagers. It has been found that the condition is prevalent in more than 85.0% people between the ages of 12 and 25. Acne can appear in forms ranging from comedones to cystic lesions, depending on its severity.

Retinoids and antibiotics remain the mainstays of acne treatment. Retinoids led the therapeutic classes in 2017, and it is expected to continue this trend through 2025. The therapeutic landscape is witnessing a shift toward combination treatment due to higher efficacy, convenient dosing, and fewer adverse effects.

By mode of administration, topical drugs currently dominate the market. Severe cases see the use of systemic medications such as oral antibiotics, hormonal agents, or other drugs. However, emergence of biologics (Gevokizumab and RA-18C3) will fuel the injectable route of administration. Biologics offer improved clinical advantage over conventional topical treatments since they target inflammatory mechanisms with disease modifying ability.

Discontinuation or termination of key pipeline candidates on account of unsuccessful clinical trials is a major restraint this market faces. Upon launch, Olumacostat glasaretil (Dermira; topical lipid synthesis inhibitor) was expected to be the first topical anti-acne drug with isotretinoin-like results without significant side effects. However, the drug failed to meet clinical endpoints, leading to discontinuation in March 2018. Similarly, SNA-001 (Sienna; silver nanoparticles solution) was deemed unsuccessful in two key trials wherein it was tested in conjunction with 810nm and 1064nm lasers in July 2018. Thesan withdrew TSN2898 from Phase II trials due to drug unavailability. Xenon discontinued development of XEN801 after the drug failed Phase II clinical trials.

Despite being one of the most common dermatological diseases in the world, innovation in acne treatment has been rather limited over the past decade. Drug companies are currently exploring novel treatment approaches including stearoyl CoA desaturase inhibition, melanocortin receptor antagonism, and anti-IL-1 monoclonal antibodies. Impending launch of late-stage pipeline products indicate a promising future for the global acne drugs market.

Acne Drugs Market Report Highlights:

  • Inflammatory acne dominated the market and accounted for a share of 65.4% in 2023. The factors attributing to the growth of the segment are bacterial skin infections that can cause inflammatory acne.
  • Over the counter (OTC) drugs dominated the market and accounted for a share of 35.9% in 2023.
  • Topical segment dominated the market and accounted for a share of 47.5% in 2023. The segment growth can be attributed to rising demand for topical products due to their ease of use, accurate dosage, and high availability as an over-the-counter drug.
  • Retail pharmacies dominated the market and accounted for a share of 37.5% in 2023.
  • North America acne drugs market dominated the market in 2023. The acne drugs market growth is attributed to the rising prevalence of acne, developed healthcare infrastructure, and the strong presence of companies involved in the acne drugs market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Acne Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Acne Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Acne Drugs Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Acne Drugs Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Inflammatory Acne
    • 4.3.1. Inflammatory Acne Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Non-inflammatory Acne
    • 4.4.1. Non-inflammatory Acne Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Acne Drugs Market: Therapeutic Class Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Acne Drugs Market: Therapeutic Class Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Topical Retinoids
    • 5.3.1. Topical Retinoids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Oral Antibiotics
    • 5.4.1. Oral Antibiotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Oral Retinoids
    • 5.5.1. Oral Retinoids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Over the Counter (OTC) Drugs
    • 5.6.1. Over the Counter (OTC) Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Acne Drugs Market: Mode of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Acne Drugs Market: Mode of Administration Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Topical
    • 6.3.1. Topical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Injectable
    • 6.5.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Acne Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Acne Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Online Pharmacies
    • 7.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Acne Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Acne Drugs Market Share, By Region, 2023 & 2030, (USD Million)
  • 8.2. North America
    • 8.2.1. North America Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. China
      • 8.4.2.1. China Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Japan Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Australia Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Saudi Arabia
      • 8.6.2.1. Saudi Arabia Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. UAE
      • 8.6.3.1. UAE Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. South Africa
      • 8.6.4.1. South Africa Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. GALDERMA
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Johnson & Johnson Services, Inc.
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. GSK plc.
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Pfizer Inc.
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. AbbVie Inc.
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Sun Pharmaceutical Industries Ltd.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. Bausch Health Companies Inc.
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Nestle Skin Health S.A.
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Bayer AG
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Viatris Inc.
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives
    • 9.4.11. Teva Pharmaceutical Industries Ltd.
      • 9.4.11.1. Participant's Overview
      • 9.4.11.2. Financial Performance
      • 9.4.11.3. Product Benchmarking
      • 9.4.11.4. Recent Developments/ Strategic Initiatives
    • 9.4.12. F. Hoffmann-La Roche Ltd
      • 9.4.12.1. Participant's Overview
      • 9.4.12.2. Financial Performance
      • 9.4.12.3. Product Benchmarking
      • 9.4.12.4. Recent Developments/ Strategic Initiatives
    • 9.4.13. LEO Pharma A/S
      • 9.4.13.1. Participant's Overview
      • 9.4.13.2. Financial Performance
      • 9.4.13.3. Product Benchmarking
      • 9.4.13.4. Recent Developments/ Strategic Initiatives
    • 9.4.14. Perrigo Company plc
      • 9.4.14.1. Participant's Overview
      • 9.4.14.2. Financial Performance
      • 9.4.14.3. Product Benchmarking
      • 9.4.14.4. Recent Developments/ Strategic Initiatives